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Abstract The effects of HIV-1 encoded proteins NCp7, vpr and 
NCp7:vpr complex on the activity of protein phosphatase-2A(l 
have been tested. We report that NCp7 is an activator of protein 
phosphatase-2A0 and that vpr activated protein phosphatase-2A0 
only slightly. We also report that NCp7 and vpr form a tight 
complex which becomes a more potent activator of protein 
phosphatase-2A0 than NCp7 alone. The ability of NCp7 to 
activate protein phosphatase-2A0 is regulated by vpr. The C-
terminal portion of vpr prevents NCp7 from activating protein 
phosphatase-2A0 while the N-terminal portion of vpr potentiates 
the effect of NCp7 on the activity of protein phosphatase-2A0. 
Our findings indicate that vpr may be acting as a targeting 
subunit which directs NCp7 to activate protein phosphatase-2A0. 
In view of the fact that protein phosphatase-2A functions as an 
inhibitor of G0 to M transition of the cell cycle and is involved in 
other key cellular processes such as the control of RNA 
transcription, the results presented in this report may explain 
how HIV-1 causes cell cycle arrest which may lead to CD4+ T 
cell depletion and also how it disturbs normal cellular processes 
of its host cell. 
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1. Introduction 
HIV-1 encoded nucleocapsid protein (NCp7) is a small bas-
ic protein with two zinc fingers of the CX2CX4HX4C type 
that are linked by a short basic sequence [1,2]. Mutations of 
key residues within the NCp7 molecule result in poorly infec-
tious or non-infectious viruses [3,4]. NCp7 functions in RNA 
dimerization and packaging of the viral genomes, the anneal-
ing of replication primer tRNA onto the primer binding site 
(PBS) and the initiation of reverse transcription [1-5]. NCp7 
may have other functions. It has been demonstrated that 
NCp7 interacts with another HIV-1 encoded protein termed 
vpr [6]. Several laboratories have shown that vpr causes cell 
cycle arrest at the G2 to M transition in several cell types [7-
13]. Because okadaic acid, a potent inhibitor of protein phos-
phatase-2A, can reverse the action of vpr, it is possible that 
vpr acts by modulating directly or indirectly the activity of 
protein phosphatase-2A which is an inhibitor of the G2 to M 
transition of the cell cycle [8,14,15]. Both NCp7 and vpr have 
stretches of basic residues that are important for their func-
tions and it also happens that protein phosphatase-2Ao which 
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has low basal activity requires polycations for full activity 
[3,4,16]. Protamine is an example of a highly basic protein 
which can act as an activator of protein phosphatase-2A in 
vitro [16]. The sequences of protamine, NCp7 and vpr resem-
ble each other in terms of the clustering of the basic arginine 
residues [1,2,17,18]. We therefore tested whether NCp7, vpr 
and NCp7:vpr can act as activators of protein phosphatase-
2A. 
2. Materials and methods 
2.1. Materials 
ATP, benzamidine, poly-L-lysine agarose, protamine agarose, 
DEAE Sepharose, Sephacryl S-300 and protamine were purchased 
from Sigma. [γ-32Ρ]ΑΤΡ was purchased from New England Nuclear. 
Protease inhibitor 4-(2-aminoethyl)-benzenesulfonyl fluoride (ABF) 
was purchased from Interchim (France). All the other reagents were 
of the highest grade. 
2.2. Protein preparations 
32P-labeled phosphorylase a was prepared by phosphorylation of 
phosphorylase b with phosphorylase kinase as described in [19]. 
HIV-1 encoded protein NCp7, the N-terminal portion of vpr (vprl-
51) and the C-terminal portion of vpr (vpr52-96) were prepared by 
chemical synthesis on an automated Applied Biosystems Solid Phase 
Peptide Synthesizer as described previously [20]. Full length vpr was 
prepared by overexpression in bacteria as described previously [21]. 
HIV-1 encoded protein complex NCp7:vpr was prepared by incubat-
ing 15 μg of NCp7 and 15 μg of vpr in 50 mM imidazole-Cl pH 7.3, 
0.2 mM EGTA, 0.1% (v/v) 2-mercaptoethanol and 10% (v/v) glycerol 
for 30 min at 30°C. The incubation mixture was then gel filtered 
through a Superose 12 column equilibrated in incubation buffer 
plus 0.2 M NaCl. Fractions containing NCp7:vpr complex were ana-
lyzed by SDS-PAGE, pooled and concentrated by vacuum dialysis. 
2.3. Measurement of protein concentrations 
Protein was determined by the method of Bradford [22]. 
2.4. Assay of protein phosphatase-2'AQ 
The assay of protein pnosphatase-2A0 consisted of 0.02 ml of en-
zyme solution in 50 mM imidazole-Cl pH 7.3, 0.2 mM EGTA, 1 mg/ 
ml bovine serum albumin and 0.1% (v/v) 2-mercaptoethanol (assay 
buffer), 0.02 ml of protamine at 10 μg/ml in assay buffer and 0.02 ml 
of 32P-labeled phosphorylase a at 3 mg/ml in assay buffer containing 
15 mM caffeine. The assay components were preincubated for 10 min 
prior to initiating the reaction with [32P]phosphorylase a. One unit of 
protein phosphatase is the amount of enzyme that catalyzes the re-
lease of 1 nmol of phosphate from phosphorylase a per minute [19]. 
When testing the effects of NCp7, vpr and NCp7:vpr complex, 
these molecules were added instead of protamine and incubated as 
described above. 
2.5. SDS-PAGE 
SDS-PAGE was performed as described in [23]. 
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2.6. Purification of protein phosphatase-2 AQ from pig brain 
Pig brains (2 kg) from freshly killed animals were obtained from the 
local slaughterhouse, cut into small pieces and homogenized in a 
Waring blender in 2 volumes of 50 mM imidazole-Cl pH 7.5, 2 mM 
EDTA, 2 mM EGTA, 0.1% (v/v) 2-mercaptoethanol and the protein-
ase inhibitors benzamidine (1 mM) and ABF (0.1 mM). All operations 
were performed in the cold room. The homogenate was centrifuged 
for 30 min at 6000 Xg and the supernatant was collected and filtered 
through glass wool. The filtrate was applied to a DEAE Sepharose 
(10X 15 cm) equilibrated with buffer A (25 mM imidazole-Cl pH 7.2, 
0.2 mM EGTA, 0.1% (v/v) 2-mercaptoethanol, 1 mM benzamidine 
and 0.1 mM ABF. The column was washed with 10 liters of buffer 
A plus 0.025 mM NaCl and then eluted with buffer A plus 0.3 M 
NaCl. The active fractions were collected and concentrated by 60%o 
ammonium sulfate saturation. The concentrate was dialyzed exten-
sively overnight against buffer A plus 10% (v/v) glycerol (buffer B). 
The dialysate was centrifuged at 100000Xg for 1 h and loaded onto a 
DEAE Sepharose column (2.5 X 50 cm) equilibrated in buffer B. The 
column was washed with buffer B plus 0.025 M NaCl and then devel-
oped with a 1000 ml linear gradient of buffer B plus 0.025 M NaCl to 
buffer B plus 0.4 M NaCl. Two major peaks of protamine stimulated 
protein phosphatase activity were detected, the first eluting at 0.13 M 
NaCl and the second at 0.22 M NaCl. We established that the first 
peak is protein phosphatase-2A0 and the second peak is protein phos-
phatase-2Ai. The peak corresponding to protein phosphatase-2Ao 
was pooled, diluted 3-fold in buffer B and then loaded onto a poly-
L-lysine agarose column (1.5X30) equilibrated in buffer B. The col-
umn was washed with buffer B plus 0.15 M NaCl and then eluted with 
a linear gradient of buffer B plus 0.15 M NaCl to buffer B plus 0.6 M 
NaCl. The active fractions eluting at around 0.25 M NaCl were 
pooled, diluted 2-fold in buffer B and loaded onto a protamine agar-
ose column (1.5X20 cm) equilibrated in buffer B. The column was 
washed with buffer B plus 0.4 M NaCl and eluted with a 400 ml 
gradient of buffer B plus 0.4 M NaCl to buffer B plus 1.0 M NaCl. 
The active fractions eluting at around 0.65 M NaCl were pooled, 
concentrated by vacuum dialysis to about 4 ml and loaded onto a 
Sephacryl S-300 column (2.5X88) equilibrated in 50 mM imidazole-Cl 
pH 7.2, 0.2 mM EGTA, 0.2 M NaCl, 10% (v/v) glycerol, 1 mM 
benzamidine and 0.1 mM ABS. The active fractions were collected, 
concentrated by vacuum dialysis, dialysed against buffer A plus 50%) 
(v/v) glycerol and stored as such at —20°C. Protein phosphatase-2Ao 
remained active for several months. 
3. Results 
Protein phosphatase-2A is one of the four major types of 
protein phosphatases in the cell [16,24]. Many subtypes of 
protein phosphatase-2A exist in the cell and these have been 
termed protein phosphatase-2Ao, protein phosphatase-2Ai, 
protein phosphatase-2A2 and protein phosphatase-2AM 
[16,24-26]. To test whether N C p 7 or vpr can act as activators 
of protein phosphatase-2A, it is important that our prepara-
tion of protein phosphatase-2A has a low basal activity. Pro-
tein phosphatase-2Ao has very low basal activity compared to 
the other subtypes [16,24]. A survey of the relative activity 
and abundance of protein phosphatase-2A in various tissues 
indicated that brain tissue has a large amount of protein 
Fig. 1. SDS-PAGE pattern of pooled active fractions at each step 
of purification of protein phosphatase-2A0. The gel was stained 
with Coomassie blue. Lane M, protein standards, from top to bot-
tom: phosphorylase b, bovine serum albumin, ovalbumin, carbonic 
anhydrase, soybean trypsin inhibitor and bovine oc-lactalbumin; lane 
1, first DEAE Sepharose step; lane 2, second DEAE Sepharose 
step; lane 3, poly-L-lysine agarose step; lane 4, protamine agarose 
step; lane 5, Sephacryl S-300 step. The bars on the right indicate 
the migration positions of the 60 kDa A subunit, the 53 kDa B' 
subunit, the 48 kDa D subunit and the 36 kDa C subunit. The C 
subunit is the catalytic subunit whereas the other subunits are regu-
latory subunits. 
phosphatase-2A that has essentially low specific activity (un-
published data). We therefore chose to purify protein phos-
phatase-2A0 from pig brain by successive chromatographies 
of a pig brain extract on D E A E Sepharose (batch elution), 
D E A E Sepharose (gradient elution), poly-L-lysine agarose, 
protamine agarose and Sephacryl S-300. The purification of 
protein phosphatase from pig brain is summarized in Table 1 
and Fig. 1. The preparation of pig brain protein phosphatase-
2A0 exhibited four major proteins of apparent molecular 
masses 60 kDa, 53 kDa, 48 k D a and 36 k D a that were in 
stoichiometric amounts as well as a number of more minor 
bands. The 60 k D a protein represents the A subunit, the 53 
k D a the B ' subunit and the 36 k D a the C catalytic subunit 
[16,24]. We could not ascertain the identity of the 48 k D a 
protein. It may represent a novel subunit of protein phospha-
tase-2A0 which functions as an inhibitor of the catalytic sub-
unit (manuscript in preparation). We have tentatively termed 
it the D subunit awaiting further analysis of its primary struc-
ture. As expected, the specific activity of the enzyme was 
about 110 units per mg protein, an order of magnitude lower 
than those from other tissues [16,24,25]. The enzyme prepara-
tion is therefore ideal for testing our hypothesis. 
Table 1 
Purification of protein phosphatase-2A0 from pig brain 
1. 
2. 
3. 
4. 
5. 
Step 
First DEAE Sepharose 
Second DEAE Sepharose 
Poly-L-lysine agarose 
Protamine agarose 
Sephacryl S-300 
Volume 
(ml) 
260 
150 
67 
50 
10 
Protein 
(mg) 
13 000 
450 
44 
5.60 
0.85 
Activity 
(units) 
1945 
827 
523 
478 
94 
Specific activity 
(units/mg) 
0.15 
1.84 
11.89 
85.36 
110.59 
Purification 
(fold) 
1 
12 
79 
569 
734 
Yield 
(%) 
100 
43 
27 
25 
5 
2 kg of pig brain was obtained from freshly killed animals from the local slaughterhouse and homogenized in two volumes of homogenization 
buffer as described in Section 2. 
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Fig. 2. Effects of HIV-1 encoded proteins NCp7 and vpr on the ac-
tivity of protein phosphatase-2A0. NCp7 was prepared and purified 
as described in [29]. The protein vpr was overexpressed in bacteria 
and purified as described in [30]. Protein phosphatase-2A0 was as-
sayed as described in [21] in the presence of various concentrations 
of NCp7 (circles) or vpr (squares) as indicated. 100% protein phos-
phatase-2A0 activity is equivalent to 0.02 unit. 
tein phosphatase-2A0 significantly (data not shown). The con-
centration of protein phosphatase-2A0 is estimated to be 
around 1 μΜ in the cell and its activation by NCp7 :vpr com-
plex occurs at sub-μΜ concentration. The effect of NCp7:vpr 
complex on the activity of protein phosphatase-2A0 is there-
fore not a substrate directed effect since the concentration of 
the substrate in the assay is over 10 μΜ [19]. 
4. Discussion 
This is the first report describing the activation of protein 
phosphatase-2A0 by two HIV-1 encoded proteins NCp7 and 
vpr. The significance of this work is that protein phosphatase-
2A is activated by a complex of the viral proteins which may 
occur at concentrations that prevail in the cell. Protein phos-
phatase-2A is an inhibitor of the G2 to M transition of the cell 
cycle and it is also involved in the control of RNA transcrip-
tion [14,15,28,29]. Our work shows that vpr does not by itself 
significantly activate protein phosphatase-2A (at the most, 
there was an activation of 1.5-fold). However, it is able to 
modulate the activity of protein phosphatase-2A because of 
its ability to form a tight complex with another HIV-1 en-
coded protein, NCp7. Vpr may therefore be acting as a tar-
geting unit that directs NCp7 to activate protein phosphatase-
2A. The finding that protein phosphatase-2A0 is activated by 
NCp7:vpr complex is consistent with the proposed roles of 
these two proteins in HIV-1 physiology and pathophysiology. 
As shown in Fig. 2, NCp7 was a better activator of protein 
phosphatase-2A0 than vpr with half-maximal activation oc-
curring at about 0.45 μΜ and 0.25 μΜ for NCp7 and vpr 
respectively. NCp7 activated protein phosphatase-2A0 by al-
most 7-fold whereas vpr activated protein phosphatase-2A0 by 
only 1.5-fold. NCp7 has been reported to interact with the full 
length vpr [6]. We therefore prepared NCp7:vpr complex by 
incubation of the two proteins at 30°C as described in the 
legend to Fig. 3 which shows that the NCp7:vpr complex 
can activate protein phosphatase-2A0 with half-maximal acti-
vation occurring at around 0.14 μΜ. Maximal activation of 
protein phosphatase-2Ao was about 12-fold and occurred at 
around 0.3 μΜ. The NCp7:vpr complex is therefore a much 
more potent activator of protein phosphatase-2A0 than NCp7 
alone. These data collectively indicate that vpr modulates the 
ability of NCp7 to activate protein phosphatase-2A0 by low-
ering its ΚΆ for the enzyme. However, at high concentration 
(above 0.3 μΜ), the activation of the enzyme by the 
NCp7:vpr complex was reversed. This dual effect of the 
NCp7:vpr complex is also observed with the other activators 
of protein phosphatase-2A and also in the case of the regula-
tion of protein phosphatase-li by its regulatory protein 
[16,24,27]. The dual effect of a protein regulator on a protein 
phosphatase can be explained by the presence of more than 
one binding site on the enzyme for the regulator protein. The 
high affinity binding site would be responsible for activation 
while the low affinity binding site would be responsible for 
inactivation. As shown in Fig. 4, at a concentration of above 
1 μΜ, the C-terminal domain of vpr acts to prevent the acti-
vation of protein phosphatase-2A0 by NCp7 while the N-
terminal domain of vpr does not prevent but potentiates the 
activation of protein phosphatase-2A0 by NCp7. The N- and 
C-terminal domains of vpr do not by themselves activate pro-
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Fig. 3. Effect of HIV-1 encoded protein complex NCp7:vpr on the 
activity of protein phosphatase-2A0. 15 μg of NCp7 and 15 μg of 
vpr were incubated together in 50 mM imidazole-Cl pH 7.3, 0.2 
mM EGTA, 0.1% (v/v) 2-mercaptoethanol for 30 min at 30°C. The 
complex of NCp7:vpr was then isolated by gel filtration through a 
Superose-12 column, concentrated by vacuum dialysis and used in 
the protein phosphatase-2Ao assay. NCp7:vpr complex elutes as a 
species of apparent molecular mass 110 kDa on Superose 12. This 
value was used to calculate the molar concentration of NCp7:vpr 
complex. Protein phosphatase-2A0 was assayed as described in [21] 
in the presence of various concentrations of NCp7:vpr complex (cir-
cles) or NCp7 alone (squares). 
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Fig. 4. Effect of HIV-1 encoded protein NCp7 on the activity of 
protein phosphatase-2A0 in the presence of the N-terminal and C-
terminal portions of vpr. NCp7 was preincubated for 10 min with 
equimolar amounts of the N-terminal portion of vpr (vpr-1-51) (cir-
cles) or the C-terminal portion of vpr (vpr52-96) (squares) and then 
mixed with protein phosphatase-2A0. Following an incubation time 
of 10 min, the activity of protein phosphatase-2Ao was measured as 
described in [21]. vprl-51 and vpr52-96 were prepared by chemical 
synthesis on an automated solid phase Applied Biosystems peptide 
synthesizer. 
It explains how HIV-1 causes cell cycle arrest at the G2 to M 
transition in its host cells which may account for the severe 
depletion of CD4 + T cells seen in the majority of HIV-1 in-
fected individuals. It has been suggested that HIV-1 induced 
cell cycle arrest of activated CD4 + T lymphocytes would result 
in non-clonal expansion of the infected cells [8]. The conse-
quence of stopping the clonal expansion of certain CD4 + T 
cells could be a cascade of events that may have catastrophic 
effects on cellular processes that control the proliferation of 
these cells and also of other cells that depend on factors that 
are produced by the infected cells. Our results may also ex-
plain how HIV-1 upregulates viral replication. Dephosphoryl-
ation of phosphorylation dependent transcription factors that 
bind to negative regulatory elements on the LTR by protein 
phosphatase-2A would result in upregulation of viral RNA 
transcription. Alternatively, dephosphorylation of dephos-
phorylation dependent transcription factors that bind to pos-
itive regulatory elements on the LTR by protein phosphatase-
2A would also result in upregulation of viral RNA transcrip-
tion [28,29]. The interaction of viral proteins with protein 
phosphatase-2A may underlie the mechanism by which var-
ious viruses interact and interfere with their hosts' normal 
cellular processes. In addition to HIV-1, other viruses such 
as simian virus 40, polyoma virus and adenovirus also inter-
fere with their hosts' cellular machinery by targetting one of 
the subunits of protein phosphatase-2A and/or changing the 
specificity of the enzyme [31,32]. 
The finding that HIV-1 encoded protein complex NCp7:vpr 
is an activator of protein phosphatase-2A0 is of significance 
because although the different subtypes of protein phospha-
tase-2A were identified many years ago and are known to be 
involved in the control of many key cellular reactions that 
may be linked to carcinogenesis and HIV-1 pathophysiology, 
the mechanisms that underlie these involvements have re-
mained obscure [8,33]. The principal reason has been that 
no physiological regulators that may activate these latent en-
zymes could be identified. The present work and those demon-
strating that vpr alone can cause cell cycle arrest at the G2 to 
M transition would suggest that a molecular equivalent of 
NCp7 may be present in the cell to regulate the activities of 
the different subtypes of protein phosphatase-2A. 
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